Drugs / succinobucol
succinobucol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00525577 | Aug 2007 → Jun 2008 | diabetes mellitus | AtheroGenics | Unknown | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00066898 | Jun 2003 → Dec 2006 | atherosclerosis, intermediate coronary syndrome, myocardial infarction | AtheroGenics | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | succinobucol | “Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with...” PMID 18502300 ↗ May 2008 |
| Known as | AGI-1067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00525577 ↗ |
| Known as | AGI-1067 (succinobucol) | “AGI-1067 (succinobucol)” NCT00525577 ↗ |
| Modality | Small molecule | — CHEMBL83626 ↗ |